In a surprising analysis it was determined that the overall survival (OS) between African American and Caucasian men with metastatic castration-resistant prostate cancer (mCRPC) favors African Americans!
Endocyte, Inc. announced that it has enrolled the first man into its phase 3 VISION study of 177Lu-PSMA-617 as a clinical therapy. Cancer ABCs has had a number of men asking about the trial.
VISION is an open-label, randomized trial assessing the addition of radiolabeled prostate-specific membrane antigen to standard therapy for PSMA-positive, previously treated metastatic castration-resistant prostate cancer (mCRPC). The study will enroll 750 men in total, with the primary endpoint being overall survival.
Currently, there are six different trials evaluating 177Lu-PSMA-617 actively recruiting men worldwide. In the United States they are at Weill Cornell Medical Center in New York, UCLA in Los Angles, and one site in Houston Texas. There are also trials in multiple locations in the UK, in Italy and in Australia. For additional trial information and locations go to
Joel T. Nowak, MA, MSW wrote this Post. Joel is the CEO/Executive Director of Cancer ABCs. He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and the rare cancer Appendiceal cancer.
Provenge (Sipuleucel-T) is the first FDA approved cancer vaccine and it is still the only immune therapy approved for Prostate Cancer. In a post-hoc analysis it was demonstrated that those men who have lower PSA scores had a superior overall survival. The analysis also showed that men who had Provenge treatment have a lower risk of cardiovascular events.
Researchers have recently found that men under the age of 20 years who have an appendicitis are up to nine times more likely to develop prostate cancer later in life. The study that came to this conclusion was performed by scientists at Orebro University in Sweden. It is one of the first to highlight this increase in the risk for the development of prostate cancer.
Black men are more likely to be diagnosed with prostate cancer at a younger age, with an advanced stage, and with a higher grade. Black men are also twice as likely to die from prostate cancer than white men. Despite these facts, these two studies show that certain treatments for advanced metastatic prostate cancer may work better in black men.
President Trump has signed the Right to Try Law which is now the law of the land, or is it?
The U.S. Food and Drug Administration (FDA) has approved a generic version of Zytiga, the new drug’s name is Yonsa. It is a novel formulation of abiraterone acetate that needs to be used in combination with methylprednisolone for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).
There are a number of items including Medicaid Expansion (or the lack of it), Family Leave and the latest attempt by certain states to screw people with pre-existing and serious chronic illness despite the federal laws protecting our medical insurance.
Statins have been in the prostate cancer news feeds for a long time. They are believed to potentiate the effects of the anti-hormonal agents used to treat metastatic castration-resistant prostate cancer (mCRPC). Different stages of prostate cancer as well as different treatment exposures might change the efficacy of statins.
Why doesn’t someone newly diagnosed with prostate cancer automatically receive chemotherapy along with hormone therapy (ADT)? There is a good reason.
Men with metastatic prostate cancer (mCRPC) who do not respond to hormone therapy (ADT) or who experience early progression (≤1year) have a poor prognosis. There is no consensus regarding the proper next therapy for these men.
The technology, PET/CT exemplifies one of the most sensitive of the diagnostic modalities we have to assess the spread of recurrent prostate cancer.
However, there is an assumption that even PET/CT, despite its sensitivity, still under-estimates the actual tumor burden. There is an additional hypothesis that the under estimation of tumor burden increases progressively by the number of positive nodes that are visualized by preoperative imaging.
In men with node positive recurrent prostate cancer researchers assessed the value of using metastasis-directed therapy (MDT; salvage node surgery or radiation) compared to the standard of care using hormone therapy (ADT).
Having positive lymph node metastasis (LNM or pN1) after a radical prostatectomy (RP) to treat prostate cancer is a poor prognostic indicator. Knowing what the next best course of treatment is if you are in this situation remains questionable. To begin to understand and better answer this problem a group of researchers performed a comparative analysis of three of the current management strategies for men with positive lymph nodes after RP.
There was a large meta-analysis recently published that compared the efficacy of abiraterone acetate (Zytiga), enzalutamide (Xtandi), cabazitaxel (Jevtana) and Radium-223 (Xofigo) in the treatment of castration-resistant, docetaxel-resistant metastatic prostate cancer.
There is an ongoing conversation in an Advanced Prostate Cancer support group which we participate in where there has been a discussion about some individuals’ experience in dealing with liver metastases (Mets). The main take away from this conversation is that if you do develop liver metastases you should ask your doctor about adding Carboplatin to Taxotere Chemotherapy.
Since abiraterone acetate (Zytiga) was approved for men with metastatic prostate cancer, it is well known that taking the drug with food in your stomach as opposed to having an empty stomach enhances the amount of drug that becomes active. Given the very high cost of Zytiga, many men have been tempted to take fewer pills along with a meal.
There is a sad truth about the current state of affairs for the treatment of non-metastatic castration-resistant prostate cancer. Our treatments can best be described as being antiquated.
Once a man with metastatic prostate cancer becomes castrate resistant (mCRPC) it is common to add a bisphosphonate like injectable zoledronic acid (Zometa) or denosumab (Xgeva) to his drug regimen. Like all other drugs, bisphosphonates have unwanted side effects, some which can be mediated.